Yunpeng Zhang

Yunpeng Zhang

Auto-generated profile, based on publicly available information

Yunpeng Zhang

Nanjing BenQ Medical Center, The Affiliated BenQ Hospital of Nanjing Medical University, Nanjing, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2021 in Science Signaling
Verified
Journal Article
Closed access
PDF file
HRHannes G. Roggenkamp
Hannes G. Roggenkamp
IKImrankhan Khansahib
Imrankhan Khansahib
LCLola C. Hernandez C.
Lola C. Hernandez C.
YZYunpeng Zhang
Yunpeng Zhang
DLDmitri Lodygin
Dmitri Lodygin
AGAndreas H. Guse
Andreas H. Guse
NAADP-evoked Ca2+ release through type 1 ryanodine receptors (RYR1) is a major mechanism underlying the earliest signals in T cell activation, which are the formation of Ca2+ microdomains. In our characterization of the molecular machinery underlying NAADP action, we identified an NAADP-binding protein, called hematological and neurological expressed 1–like protein (HN1L) [also known as Jupiter microtubule-associated homolog 2 (JPT2)]. Gene deletion of Hn1l/Jpt2 in human Jurkat and primary rat T cells resulted in decreased numbers of initial Ca2+ microdomains and delayed the onset and decreased the amplitude of global Ca2+ signaling. Photoaffinity labeling demonstrated direct binding of NAADP to recombinant HN1L/JPT2. T cell receptor/CD3–dependent coprecipitation of HN1L/JPT2 with RYRs and colocalization of these proteins suggest that HN1L/JPT2 connects NAADP formation with the activation of RYR channels within the first seconds of T cell activation. Thus, HN1L/JPT2 enables NAADP to activate Ca2+ release from the endoplasmic reticulum through RYR.

21 November 2024 in Journal of Bone and Joint Surgery
Verified
Journal Article
Closed access
RJRuigang Jia
Ruigang Jia
DLDong Li
Dong Li
PHPeng He
Peng He
XWXin-Qiang Wang
Xin-Qiang Wang
YZYunpeng Zhang
Yunpeng Zhang
JTJiwei Tian
Jiwei Tian
Background: No studies have evaluated the impact of the cement distribution as classified on the basis of the fracture bone marrow edema area (FBMEA) in magnetic resonance imaging (MRI) on the efficacy of percutaneous vertebral augmentation (PVA) for acute osteoporotic vertebral fractures. Methods: The clinical data of patients with acute, painful, single-level thoracolumbar osteoporotic fractures were retrospectively analyzed. The bone cement distribution on the postoperative radiograph was divided into 4 types according to the distribution of the FBMEA on the preoperative MRI. The primary outcomes were the postoperative visual analog scale (VAS) for pain and Oswestry Disability Index (ODI) scores. Cement leakage, adjacent vertebral fractures (an important concern in complications after vertebroplasty and a subset of new fractures), and recollapse of the treated vertebra were also evaluated. Results: A total of 128 patients, 80.5% of whom were female, were included and had follow-up for 24 months. The mean patient age (and standard deviation) was 74.2 ± 8.6 years. The cement distribution was classified as Type I in 18 patients, Type II in 26, Type III in 46, and Type IV in 38. At the primary time point (6 months), there was a significant difference in the ODI score favoring the Type-III and Type-IV groups compared with the Type-I and Type-II groups (adjusted 95% confidence interval [CI]: Type I versus Type II, −2.40 to 4.50; Type I versus Type III, 1.35 to 7.63; Type I versus Type IV, 1.27 to 7.92; Type II versus Type III, 0.67 to 6.21; Type II versus Type IV, 0.63 to 6.46; adjusted p < 0.0083), whereas no significant differences were found between the 4 groups in the VAS pain score. The Type-II and Type-IV groups had a higher incidence of cement leakage, and the Type-III and Type-IV groups had a lower incidence of vertebral recollapse. Conclusions: An adequate distribution of bone cement is advantageous for functional improvement, short-term pain relief, and a lower rate of vertebral recollapse. The FBMEA appears to be a feasible reference marker for evaluating the performance of the PVA procedure. Level of Evidence: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.


2 September 2026
Verified
Other
Open access
PDF file
YWYiting Wei
Yiting Wei
JCJing Chen
Jing Chen
YZYunpeng Zhang
Yunpeng Zhang
YLYueming Liu
Yueming Liu
FZFengjiao Zhu
Fengjiao Zhu
LWLixin Wang
Lixin Wang
Tα-1 facilitates migration of cutaneous cDC1s during the phagocytosis of ABs.

2 September 2026
Verified
Other
Open access
PDF file
YWYiting Wei
Yiting Wei
JCJing Chen
Jing Chen
YZYunpeng Zhang
Yunpeng Zhang
YLYueming Liu
Yueming Liu
FZFengjiao Zhu
Fengjiao Zhu
LWLixin Wang
Lixin Wang
Tα-1 augments DCs-mediated T-cell activation through a ssRNA-TLR7 axis.

2 September 2026
Verified
Other
Open access
PDF file
YWYiting Wei
Yiting Wei
JCJing Chen
Jing Chen
YZYunpeng Zhang
Yunpeng Zhang
YLYueming Liu
Yueming Liu
FZFengjiao Zhu
Fengjiao Zhu
LWLixin Wang
Lixin Wang
Tα-1 promotes splenic cDC1 maturation during the phagocytosis of ABs.